The Pharmaceutical industry must prioritize sustainability. Jürgen Roos, Chief Scientific Officer (CSO) of Siegfried, explains opportunities and limits of sustainability...

There are only a few chemical and pharmaceutical companies that look back at a history of 150 years. Certainly, many companies claim such a long legacy, but if you only...

Climate change, energy crisis, the call for a more environmentally compatible production method and socially responsible action do not stop at the pharmaceutical and...

The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven...

The CDMO (contract development and manufacturing organizations) business has a bright future, of that Siegfried CEO Wolfgang Wienand is certain. The economic advantages...

Swiss CDMO Siegfried has acquired a 95% stake in Dinamiqs, a compatriot biotech focused on developing and manufacturing viral vectors for cell and gene therapies.

Swiss-based, globally oriented CDMO Siegfried has broken ground or its new global Research and Development (R&D) Center for Drug Substances at its site in Evionnaz...

As part of its growth strategy, Siegfried strengthens its management team and appoints Christian Dowdeswell as Chief Business Officer Drug Substances and member of the...